What question did this study set out to answer?

This research aims to identify factors associated with hospital admissions and emergency visits in patients with inflammatory bowel disease through remote monitoring data.

January 23, 2026

P0195Factors associated with hospitalisations, emergency visits and related costs in inflammatory bowel disease: insights from the TrueColours-IBD digital monitoring programme in Oxford

Key Points

This research aims to identify factors associated with hospital admissions and emergency visits in patients with inflammatory bowel disease through remote monitoring data.
Enrolled adults with inflammatory bowel disease in the TrueColours-IBD program from June 2018 to February 2025.
Collected patient-reported data on symptoms, quality of life, and healthcare use at regular intervals.
Used random-effects logistic regression to analyze associations between health scores and healthcare utilization.
Included 3,197 patients, with 836 hospitalisations and 1,182 emergency visits recorded.
Higher odds of hospitalisation were linked with worse health-related quality of life scores.
Estimated annual costs for hospitalisations were £111,234,917 and £13,089,422 for emergency department admissions.

Abstract

Abstract Background Remote monitoring in IBD may help identify patients at risk of higher healthcare use. The TrueColours-IBD (TC-IBD) system, initiated at the Oxford University Hospitals in 2018, enables patients to report baseline case mix variables, weekly symptoms (HBI for CD; SCCAI for UC), fortnightly health-related quality of life (HRQoL - derived from the EQ-5D), and three-monthly healthcare use (ICHOM). We identified factors associated with hospitalisation, emergency department (ED) admission, and related costs using the longitudinal TC-IBD data. Methods Adults with IBD enrolled in TC-IBD (June 2018–Feb 2025) and ≥6 months of follow-up were included. Data were aggregated into 3-month panels using the most severe values within each period, and 3-month lagged variables to ensure temporal ordering. Random-effects logistic regression examined associations between HBI, SCCAI and EQ-5D scores, and subsequent hospitalisation or ED visits, adjusting for demographic and clinical covariates. Annual costs were calculated using reported hospital use and unit costs, and population-level costs estimated by applying average per-patient event rates to the UK IBD population. Analyses were performed in Stata 19. Results By Feb 2025, 3, 197 patients were included (59. 8% UC, 40. 2% CD; median IQR age 45. 5 34. 5–59. 4 years and disease duration 4, 000 1, 999–7, 277 days), contributed 48, 732 observations, with per patient a mean of 3. 41 (SD 1. 10) time periods per year and 15. 2 in total. A total of 836 hospitalisations and 1, 182 ED visits occurred among 501 and 672 patients respectively. Higher odds of hospitalisation and ED visits were associated with EQ-5D pain/discomfort and limitations in usual activities, HBI and SCCAI total and general wellbeing scores, and SCCAI-reported blood in stool. Worse overall HRQoL was associated with increased ED use, while impaired self-care and overall health, higher HBI liquid stools and SCCAI bowel frequency were associated with hospitalisations (Table 1). Estimated annual costs for the full UK IBD population were £111, 234, 917 for hospitalisations and £13, 089, 422 for ED admissions (Table 2). Conclusion This large longitudinal patient-reported dataset allowed to identify key factors - including general wellbeing and pain/discomfort in addition to total scores - associated with hospital and ED use, highlighting their potential for targeted real-time risk stratification, and enabled estimation of related costs. Integrating remote monitoring into routine care may help enable proactive and cost-effective IBD management. References: (1) Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, et al. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res. 2019 Jul 30;17 (3): 365–74. (2) NHS 2022/23 National Cost Collection Data Publication. https: //www. england. nhs. uk/publication/2022-23-national-cost-collection-data-publication-2/. Accessed 17 Nov 2025. (3) Nartey Y, Ratna M, Card TR, et al. Incidence and prevalence of inflammatory bowel disease across the United Kingdom. University of Nottingham. 2021. https: //www. crohnsandcolitis. org. uk/media/pkamxda4/uonreport2021ᵢbdᵢncidandprev. pdf. Accessed 17 Nov 2025. Conflict of interest: Mrs. Fierens, Liselotte: No conflict of interest Clarke, Philip: No conflict of interest Dunbar, Grace: No conflict of interest Kormilitzin, Andrey: I hold research grants from: - the National Institute for Health and Care Research (UK) - GlaxoSmithKline - Pfizer - Alzheimer’s Research UK Matini, Lawrence: Speaker fees: AbbVie, Galapagos, Bristol Myers Squibb Punj Sharda, Anita: No conflict of interest Travis, Simon: Research Support: AbbVie, Celgene, Celsius, ECCO, Galapagos, GSK, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UKIERI, 35Bio, Vifor, and Norman Collisson Foundation Consulting Fees: Alimentiv Apexian Apollo Arcturis AstraZeneca BMS Clario Cosmo Dova Health Endpoint Health EQrX Equillium Ferring Galapagos Genentech/Roche Gilead GSK Janssen Iterative Health Lilly Mestag Microbiotica ONO Pfizer Phesi Protagonist Sanofi Satisfai Sensyne Health Spyre Takeda Teva Theravance Tr1X Bio Speaker fees: BMS, Ferring, GSK, Janssen, Lilly, Pfizer, Sun Pharma, Takeda. Share options: Dova Health Inc. Walsh, Alissa: Grant: Alfasigma, Helmsley Trust, Johnson & Johnson, Pfizer, Takeda Personal Fees: AbbVie, Alfasigma, Bristol Meyers Squibb, Dr Falk, Ferring, Johnson & Johnson, Lilly, Pfizer, Takeda, Tillotts Violato, Mara: No conflicts

Bookmark

Cite This Study

Fierens et al. (Thu,) studied this question.

synapsesocial.com/papers/69730ef2c8125b09b0d1ec2a https://doi.org/https://doi.org/10.1093/ecco-jcc/jjaf231.376

Bookmark